|
04 Apr 2020 |
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
|
|
04 Apr 2020 |
XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
|
|
04 Apr 2020 |
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
|
|
04 Apr 2020 |
Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
|
|
04 Apr 2020 |
U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt) , the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
|
|
03 Apr 2020 |
Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
|
|
03 Apr 2020 |
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
|
|
03 Apr 2020 |
Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study
|
|
03 Apr 2020 |
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
|
|
03 Apr 2020 |
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
|
|
03 Apr 2020 |
Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
|
|
02 Apr 2020 |
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
|
|
02 Apr 2020 |
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
|
|
02 Apr 2020 |
Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
|
|
02 Apr 2020 |
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
|
|
01 Apr 2020 |
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
|
|
01 Apr 2020 |
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
|
|
01 Apr 2020 |
Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
|
|
01 Apr 2020 |
Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
|
|
01 Apr 2020 |
EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study
|
|
01 Apr 2020 |
Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination w/ CHP for Adult Patients with Previously Untreated sALCL
|
|
31 Mar 2020 |
I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
|
|
31 Mar 2020 |
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
|
|
31 Mar 2020 |
Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
|
|
30 Mar 2020 |
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
|
